Skip to main content

Table 3 Predictors of Treatment Adherence (MPR and 1-year PDC ≥80%), REACH-OUT (2010–2013)

From: Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations

  MPR PDC
VARIABLE β (95% CI) P Value OR (95% CI) P Value
Treatment cohort:
OAT Reference   Reference  
PP-N 0.36 (0.31–0.42) <0.001 10.27 (5.55–19.00) <0.001
PP-C 0.39 (0.34–0.44) <0.001 16.47 (9.12–29.75) <0.001
Assertive community treatment 3.00 (1.37–6.59) 0.006
Age (10-year increase) 0.03 (0.01–0.05) 0.008 1.29 (1.03–1.62) 0.028
Arrested in last month 0.13 (0.01–0.25) 0.029 4.17 (1.14–15.32) 0.031
Private residence 1.89 (1.15–3.13) 0.012
Black/African American 0.40 (0.24–0.67) 0.001
Heart disease 3.38 (1.36–8.72) 0.010
Substance abuse 0.44 (0.28–0.70) 0.001
Duration of schizophrenia (10-year increase) −0.03 (−0.05 to −0.01) 0.007 0.81 (0.64–1.02) 0.068
  1. Notes: Adjusted logistic regression models, including all variables listed, plus the following additional model-specific covariates. MPR: Drug Attitude Inventory-10 score; Quality of Life social interaction domain score; hospitalizations/ED visits; insurance; gender; marital status; psychiatric comorbidities; and physical comorbidities. PDC: medication satisfaction; hospitalizations/ED visits; insurance; gender; Hispanic or other race/ethnicity; psychiatric comorbidities; physical comorbidities; alcohol abuse; and frequency of strength training
  2. Abbreviations: CI confidence interval, ED emergency department, MPR medication possession ratio, OAT oral antipsychotic therapy, PDC proportion of days covered, PP paliperidone palmitate, PP-C continuous user of paliperidone palmitate, PP-N new user of paliperidone palmitate